Methionine Can Favor DNA Platination by  trans ‐Coordinated Platinum Antitumor Drugs | Zendy

Li Chan | Zendy; Li Zhanyong | Zendy; Sletten Einar | Zendy; Arnesano Fabio | Zendy; Losacco Maurizio | Zendy; Natile Giovanni | Zendy; Liu Yangzhong | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Methionine Can Favor DNA Platination by trans ‐Coordinated Platinum Antitumor Drugs

Author(s) -

Li Chan,

Li Zhanyong,

Sletten Einar,

Arnesano Fabio,

Losacco Maurizio,

Natile Giovanni,

Liu Yangzhong

Publication year - 2009

Publication title -

angewandte chemie international edition

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.831

H-Index - 550

eISSN - 1521-3773

pISSN - 1433-7851

DOI - 10.1002/anie.200902948

Subject(s) - cisplatin , chemistry , carboplatin , dna , stereochemistry , platinum , adduct , dna repair , oxaliplatin , methionine , biochemistry , chemotherapy , cancer , biology , amino acid , catalysis , genetics , colorectal cancer , organic chemistry

It happens at the Met : The DNA platination rate is substantially enhanced by methionine binding to trans ‐coordinated platinum antitumor drugs (see scheme). Platinum–methionine intermediates were also formed in a cell system and could play a major role in the mechanism of action of trans compounds.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research